Mesoblast (MESO) Long-Term Deferred Tax (2017 - 2021)
Mesoblast (MESO) posted Long-Term Deferred Tax of $80.2 million for Q4 2021, little changed sequentially from $80.2 million in Q3 2021, and little changed YoY from $80.1 million in Q4 2020.
Mesoblast (MESO) Long-Term Deferred Tax (2017 - 2021) Analysis & Trends
Mesoblast has reported Long-Term Deferred Tax for 5 years, with the latest figure at $80.2 million in Q4 2021.
- Quarterly Long-Term Deferred Tax changed 0.11% year-over-year to $80.2 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $80.2 million (changed 0.11% YoY) and the FY2021 annual result came in at $80.2 million, up 1.35% from the prior year.
- Long-Term Deferred Tax was little changed at $80.2 million in Q4 2021 per MESO's latest filing, from $80.2 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $80.2 million in Q3 2021 and troughed at $56.6 million in Q2 2018.
- A 5-year average of $73.2 million and a median of $78.2 million in 2017 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2018 and 2019: Long-Term Deferred Tax fell 27.68% in 2018, then gained 21.22% in 2019.
- Over 5 years, Long-Term Deferred Tax stood at $78.2 million in 2017, then declined by 23.17% to $60.1 million in 2018, then advanced by 21.22% to $72.9 million in 2019, then rose by 9.97% to $80.1 million in 2020, then grew by 0.11% to $80.2 million in 2021.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $80.2 million, $80.2 million, and $80.2 million for Q4 2021, Q3 2021, and Q2 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 80.21 Mn |
| Sep 30, 2021 | 80.25 Mn |
| Jun 30, 2021 | 80.16 Mn |
| Mar 31, 2021 | 80.20 Mn |
| Dec 31, 2020 | 80.12 Mn |
| Sep 30, 2020 | 79.91 Mn |
| Jun 30, 2020 | 79.10 Mn |
| Mar 31, 2020 | 74.78 Mn |
| Dec 31, 2019 | 72.85 Mn |
| Sep 30, 2019 | 67.45 Mn |
| Jun 30, 2019 | 65.43 Mn |
| Mar 31, 2019 | 62.28 Mn |
| Dec 31, 2018 | 60.10 Mn |
| Jun 30, 2018 | 56.57 Mn |
| Jun 30, 2017 | 78.23 Mn |